1 – 13 of 13
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
From iPS Cells to Rodents and Nonhuman Primates : Filling Gaps in Modeling Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Viral-based rodent and nonhuman primate models of multiple system atrophy : Fidelity to the human disease
(
- Contribution to journal › Article
- 2019
-
Mark
Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease
(
- Contribution to journal › Article
- 2015
-
Mark
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
(
- Contribution to journal › Article
-
Mark
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Animal Models of Parkinson's Disease: Limits and Relevance to Neuroprotection Studies
(
- Contribution to journal › Scientific review
-
Mark
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
- 2010
-
Mark
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
(
- Contribution to journal › Article
-
Mark
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.
(
- Contribution to journal › Article
- 2009
-
Mark
Antagonizing L-type Ca2+ Channel Reduces Development of Abnormal Involuntary Movement in the Rat Model of L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia
(
- Contribution to journal › Article
- 2008
-
Mark
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
(
- Contribution to journal › Article